Comparison of EGFR mutation status detected by ARMS in different sample types
| A. Tumour tissue versus MPE cell block | |||
|---|---|---|---|
| Tumour tissue | |||
| MPE cell block | + | − | Total |
| + | 9 | 2 | 11 |
| − | 2 | 8 | 10 |
| Total | 11 | 10 | 21 |
| NPV: 8/10 (80.0%); PPV: 9/11 (81.8%). | |||
| B. Tumour tissue versus MPE supernatant | |||
| Tumour tissue | |||
| MPE supernatant | + | − | Total |
| + | 7 | 0 | 7 |
| − | 4 | 10 | 14 |
| Total | 11 | 10 | 21 |
| NPV: 10/14 (71.4%); PPV: 7/7 (100.0%). | |||
| C. MPE cell block versus MPE supernatant | |||
| MPE cell block | |||
| MPE supernatant | + | − | Total |
| + | 9 | 0 | 9 |
| − | 4 | 14 | 18 |
| Total | 13 | 14 | 27 |
| NPV: 14/18 (77.8%); PPV: 9/9 (100.0%). | |||
| D. Tumour tissue versus plasma | |||
| Tumour tissue | |||
| Plasma | + | − | Total |
| + | 27 | 0 | 27 |
| − | 13 | 46 | 59 |
| Total | 40 | 46 | 86 |
| NPV: 46/59 (79.0%); PPV: 27/27 (100.0%). | |||
ARMS, amplification refractory mutation system; EGFR, epidermal growth factor receptor; MPE, malignant pleural effusion; NPV, negative predictive value; PPV, positive predictive value.